These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 3920542)

  • 1. [L-dopa therapy of parkinson syndrome].
    Kapfhammer HP; Kuss HJ; Rüther E
    Nervenarzt; 1985 Feb; 56(2):57-68. PubMed ID: 3920542
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of L-dopa in patients with Parkinson's disease.
    Mena MA; Muradas V; Bazan E; Reiriz J; de Yebenes JG
    Adv Neurol; 1987; 45():481-6. PubMed ID: 2950730
    [No Abstract]   [Full Text] [Related]  

  • 3. Levodopa with benserazide or carbidopa in Parkinson disease.
    Rinne UK; Mölsä P
    Neurology; 1979 Dec; 29(12):1584-9. PubMed ID: 574221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 5. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P
    Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract]   [Full Text] [Related]  

  • 6. Parkinson disease: adjunctive entacapone therapy increases risk of dyskinesia.
    Sampaio C; Ferreira JJ
    Nat Rev Neurol; 2010 Nov; 6(11):590-1. PubMed ID: 21048799
    [No Abstract]   [Full Text] [Related]  

  • 7. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK; Verma S; Cordingley GJ; Harris RI
    Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease: new treatments.
    Stewart RM
    Compr Ther; 1981 Apr; 7(4):38-44. PubMed ID: 7237986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor].
    Rabadeau Dumas JL; Rondot P; Cardon P
    Therapie; 1977; 32(2):161-72. PubMed ID: 898124
    [No Abstract]   [Full Text] [Related]  

  • 10. Problems arising during chronic treatment with L-dopa for Parkinson's disease: changes in response to treatment.
    Caraceni TA; Girotti F; Giovannini P; Parati E
    J Neural Transm Suppl; 1986; 22():189-99. PubMed ID: 3537210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of low-dose dopa therapy in Parkinson disease].
    Petit H; Rousseaux M; Mazingue A; Warot P
    LARC Med; 1983; 3(7):514-6. PubMed ID: 6645742
    [No Abstract]   [Full Text] [Related]  

  • 12. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Problems of levodopa treatment.
    Horstink MW
    Clin Neurol Neurosurg; 1984; 86(3):196-206. PubMed ID: 6091967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa treatment of Parkinson's syndrome: past and future.
    Pletscher A
    Adv Neurol; 1990; 53():469-73. PubMed ID: 2239486
    [No Abstract]   [Full Text] [Related]  

  • 16. Dystonia--L-dopa responsive or juvenile parkinsonism?
    Rondot P; Ziegler M
    J Neural Transm Suppl; 1983; 19():273-81. PubMed ID: 6583312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of benserazide and carbidopa in Parkinson's disease.
    Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
    Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
    Carlsson A
    J Neural Transm Suppl; 1983; 19():153-61. PubMed ID: 6321646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term syndrome in the treatment of parkinsonism with L-dopa and decarboxylase an inhibitor].
    Chouza C; Romero S; Gomensoro JB
    Neurol Neurocir Psiquiatr; 1976; 17(4):255-68. PubMed ID: 828242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.